Turning Point Therapeutics announced updated data on repotrectinib
Turning Point Therapeutics announced updated interim data from the Phase 1 portion of its ongoing Phase 1/2 TRIDENT-1 clinical study of lead drug candidate repotrectinib in patients with ROS1-positive non-small cell lung cancer,NSCLC,and TRK-positive patients with advanced solid tumors. The company also announced potent preclinical activity for its novel RET/SRC drug candidate, TPX-0046, in wild type and mutated RET fusions compared to proxy chemical compounds for investigational RET inhibitors."With each additional update of the ongoing Phase 1 clinical data, repotrectinib continues to encourage us with what we believe is best-in-class potential for patients with ROS1-positive advanced non-small cell lung cancer," said Athena Countouriotis, M.D., president and chief executive officer. "The preliminary data are also encouraging in the TRK-positive population where we have treated fewer patients but today reported our first confirmed response in a TKI-naive patient. With two ROS1-positive patients remaining on treatment for more than 2 years, we believe the results we announced today further distinguish repotrectinib, and are supportive of our ongoing, multi-cohort registrational Phase 2 TRIDENT-1 Study."With TPX-0046, we have demonstrated strong preclinical potency in Ba/F3 cells with the mutated KIF5B RET fusion gene and against multiple solvent front mutations that may arise from other investigational RET inhibitors and lead to treatment resistance. We believe these results position TPX-0046 for potential use in TKI-naive patients as well as those who have developed treatment resistance with solvent front mutations. Subject to clearance of the IND, we look forward to initiating our planned clinical trial later this year."